ASX:TLXBiotechs
Will Telix (ASX:TLX) Board Refresh Subtly Recast Its Governance And Growth Balancing Act?
Telix Pharmaceuticals recently announced that David Gill will join its Board as a Non-Executive Director on 11 May 2026, with plans for him to succeed Dr. Mark Nelson as Chair while Nelson remains a Non-Executive Director.
The appointment brings a veteran life sciences executive with extensive radiopharmaceutical, capital markets and governance experience onto Telix’s Board, potentially reshaping how the company balances growth ambitions with oversight as a dual-listed business.
We’ll now...